Search Results - "X Leleu"

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond by Chim, C S, Kumar, S K, Orlowski, R Z, Cook, G, Richardson, P G, Gertz, M A, Giralt, S, Mateos, M V, Leleu, X, Anderson, K C

“…Despite enormous advances, management of multiple myeloma (MM) remains challenging. Multiple factors impact the decision to treat or which regimen to use at MM…”
Get full text

Bone Marrow Microenvironment in Multiple Myeloma Progression by Ghobrial, I. M., Sacco, A., Leleu, X., Roccaro, A. M., Manier, S.

“…Substantial advances have been made in understanding the biology of multiple myeloma (MM) through the study of the bone marrow (BM) microenvironment. Indeed,…”
Get full text

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma by Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z, Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O’Dwyer, Michael, Perrot, Aurore, Venner, Christopher P, Weisel, Katja, Mace, Joseph R, Raje, Noopur, Attal, Michel, Tiab, Mourad, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Ahmadi, Tahamtan, Chiu, Christopher, Wang, Jianping, Van Rampelbergh, Rian, Uhlar, Clarissa M, Kobos, Rachel, Qi, Ming, Usmani, Saad Z

“…The addition of daratumumab to lenalinomide and dexamethasone in patients with previously untreated myeloma who were not eligible for high-dose chemotherapy…”
Get full text

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study by Kumar, S K, Dimopoulos, M A, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, E M, Mateos, M V, O'Donnell, E K, Vij, R, Lokhorst, H M, van de Donk, N W C J, Min, C, Mark, T, Turesson, I, Hansson, M, Ludwig, H, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, U, Usmani, S Z, Dytfeld, D, Badros, A Z, Moreau, P, Kim, K, Otero, P R, Lee, J H, Shustik, C, Waller, D, Chng, W J, Ozaki, S, Lee, J-J, de la Rubia, J, Eom, H S, Rosinol, L, Lahuerta, J J, Sureda, A, Kim, J S, Durie, B G M

“…Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this…”
Get full text

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma by Manier, S, Powers, J T, Sacco, A, Glavey, S V, Huynh, D, Reagan, M R, Salem, K Z, Moschetta, M, Shi, J, Mishima, Y, Roche-Lestienne, C, Leleu, X, Roccaro, A M, Daley, G Q, Ghobrial, I M

“…MYC is a major oncogenic driver of multiple myeloma (MM) and yet almost no therapeutic agents exist that target MYC in MM. Here we report that the let-7…”
Get full text

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group by Laubach, J, Garderet, L, Mahindra, A, Gahrton, G, Caers, J, Sezer, O, Voorhees, P, Leleu, X, Johnsen, H E, Streetly, M, Jurczyszyn, A, Ludwig, H, Mellqvist, U-H, Chng, W-J, Pilarski, L, Einsele, H, Hou, J, Turesson, I, Zamagni, E, Chim, C S, Mazumder, A, Westin, J, Lu, J, Reiman, T, Kristinsson, S, Joshua, D, Roussel, M, O'Gorman, P, Terpos, E, McCarthy, P, Dimopoulos, M, Moreau, P, Orlowski, R Z, Miguel, J S, Anderson, K C, Palumbo, A, Kumar, S, Rajkumar, V, Durie, B, Richardson, P G

“…The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic…”
Get full text

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) by Hájek, R, Masszi, T, Petrucci, M T, Palumbo, A, Rosiñol, L, Nagler, A, Yong, K L, Oriol, A, Minarik, J, Pour, L, Dimopoulos, M A, Maisnar, V, Rossi, D, Kasparu, H, Van Droogenbroeck, J, Yehuda, D B, Hardan, I, Jenner, M, Calbecka, M, Dávid, M, de la Rubia, J, Drach, J, Gasztonyi, Z, Górnik, S, Leleu, X, Munder, M, Offidani, M, Zojer, N, Rajangam, K, Chang, Y-L, San-Miguel, J F, Ludwig, H

“…This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in…”
Get full text

Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma by Favreau, M, Menu, E, Gaublomme, D, Vanderkerken, K, Faict, S, Maes, K, De Bruyne, E, Govindarajan, S, Drennan, M, Van Calenbergh, S, Leleu, X, Zabeau, L, Tavernier, J, Venken, K, Elewaut, D

“…A hallmark of bone marrow changes with aging is the increase in adipocyte composition, but how this impacts development of multiple myeloma (MM) is unknown…”
Get full text

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study by Ludwig, H, Weisel, K, Petrucci, M T, Leleu, X, Cafro, A M, Garderet, L, Leitgeb, C, Foa, R, Greil, R, Yakoub-Agha, I, Zboralski, D, Vauléon, S, Dümmler, T, Beyer, D, Kruschinski, A, Riecke, K, Baumann, M, Engelhardt, M

Get full text

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma by Dimopoulos, M A, Leleu, X, Palumbo, A, Moreau, P, Delforge, M, Cavo, M, Ludwig, H, Morgan, G J, Davies, F E, Sonneveld, P, Schey, S A, Zweegman, S, Hansson, M, Weisel, K, Mateos, M V, Facon, T, Miguel, J F S

“…In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based…”
Get full text

French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry by Ferment, B., Lambert, J., Caillot, D., Lafon, I., Karlin, L., Lazareth, A., Touzeau, C., Leleu, X., Moya, N., Harel, S., Perrot, A., Bories, P., Vincent, L., Lamure, S., Mohty, M., Malard, F., Manier, S., Yakoub‐Agha, I., Schiano De Colella, J.‐M., Brisou, G., Talbot, A., Decaux, O., Houot, R., Le Gouill, S., Bigot, N., Facon, T., Corre, J., Moreau, P., Arnulf, B.

“…Summary Idecabtagene vicleucel (ide‐cel), a chimeric antigen receptor T‐cell therapy targeting B‐cell maturation antigen (BCMA), received early access program…”
Get full text

Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) by González-Barca, E., Boumendil, A., Blaise, D., Trněný, M., Masszi, T., Finel, H., Michieli, M. G., Bittenbring, J. T., Gritti, G., Snowden, J. A., Bishton, M., Bruno, B., de Villambrosia, S. González, Janikova, A., Leleu, X., Anagnostopoulos, A., Poiré, X., Crysandt, M., Özkurt, Z. N., Vandenberghe, E., Itälä-Remes, M., Cahn, J. Y., Jantunen, E., Schroyens, W., Maertens, J., Esquirol, A., Dreger, P., Montoto, S., Sureda, A.

“…Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL) who…”
Get full text

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study by Macro, M., Hulin, C., Vincent, L., Charvet-Rumpler, A., Benboubker, L., Calmettes, C., Stoppa, A.-M., Laribi, K., Clement-Filliatre, L., Zerazhi, H., Honeyman, F., Richez, V., Maloisel, F., Karlin, L., Barrak, J., Chouaid, C., Leleu, X.

“…Ixazomib (IXA) is an oral proteasome inhibitor (PI) used in combination with lenalidomide and dexamethasone (IXA-Rd) for patients with relapsed and/or…”
Get full text

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel by Caers, J, Paiva, B, Zamagni, E, Leleu, X, Bladé, J, Kristinsson, S Y, Touzeau, C, Abildgaard, N, Terpos, E, Heusschen, R, Ocio, E, Delforge, M, Sezer, O, Beksac, M, Ludwig, H, Merlini, G, Moreau, P, Zweegman, S, Engelhardt, M, Rosiñol, L

“…Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary…”
Get full text

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients by Hebraud, B, Leleu, X, Lauwers-Cances, V, Roussel, M, Caillot, D, Marit, G, Karlin, L, Hulin, C, Gentil, C, Guilhot, F, Garderet, L, Lamy, T, Brechignac, S, Pegourie, B, Jaubert, J, Dib, M, Stoppa, A-M, Sebban, C, Fohrer, C, Fontan, J, Fruchart, C, Macro, M, Orsini-Piocelle, F, Lepeu, G, Sohn, C, Corre, J, Facon, T, Moreau, P, Attal, M, Avet-Loiseau, H

“…Deletions of the 1p region appear as a pejorative prognostic factor in multiple myeloma patients (especially 1p22 and 1p32 deletions) but there is a lack of…”
Get full text

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma by Leleu, X, Fouquet, G, Hebraud, B, Roussel, M, Caillot, D, Chrétien, M L, Arnulf, B, Szalat, R, Garderet, L, Benajiba, L, Pegourie, B, Regny, C, Royer, B, Caulier, A, Stoppa, A M, Garciaz, S, Touzeau, C, Chaleteix, C, Fermand, J P, Loiseau, H A, Facon, T, Attal, M, Moreau, P

Get full text

EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3 by N Raje, X Leleu, A Lesokhin, M Mohty, A Nooka, E Leip, U Conte, A Viqueira, V Blunk, S Manier

“…Introduction/Objectives: Multiple myeloma is a disease of elderly and frail people, who are often predominantly ineligible for intensive therapies. The…”
Get full text

Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience by Avet-Loiseau, H, Roussel, M, Campion, L, Leleu, X, Marit, G, Jardel, H, Dib, M, Decaux, O, Lamy, T, Tiab, M, Cony-Makhoul, P, Banos, A, Lepeu, G, Lifermann, F, Macro, M, Kolb, B, Hulin, C, Caillot, D, Traulle, C, Mathiot, C, Royer, B

Get full text

Free light chains assay: Indications and methods by Martellosio, J-P, Leleu, X, Roblot, P, Martin, M, Puyade, M

“…Serum free light chains (sFLC) assay is an important marker in plasma cell dyscrasia. It is thus recommended for the diagnosis of monoclonal gammopathy,…”
Get full text

Characterization of familial Waldenstrom's macroglobulinemia by TREON, S. P, HUNTER, Z. R, TOURNILHAC, O, PATTERSON, C. J, MANNING, R, BRANAGAN, A. R, MORTON, C. C, AGGARWAL, A, EWEN, E. P, MASOTA, S, LEE, C, DITZEL SANTOS, D, HATJIHARISSI, E, XU, L, LELEU, X

“…Familial clustering of B-cell disorders among Waldenström's macroglobulinemia (WM) patients has been reported, though the frequency and any differences in…”
Get full text